Substitutability Between Drugs, Innovation, and Fiscal Policy in the Pharmaceutical Industry
Author
Abstract
Suggested Citation
Download full text from publisher
References listed on IDEAS
- Comanor, William S. & Scherer, F.M., 2013. "Mergers and innovation in the pharmaceutical industry," Journal of Health Economics, Elsevier, vol. 32(1), pages 106-113.
- Bloom, David E. & Börsch-Supan, Axel & McGee, Patrick & Seike, Atsushi, 1970.
"Population Aging: Facts, Challenges, and Responses,"
MEA discussion paper series
201224, Munich Center for the Economics of Aging (MEA) at the Max Planck Institute for Social Law and Social Policy.
- David E. Bloom & Axel Boersch-Supan & Patrick McGee & Atsushi Seike, 2011. "Population Aging: Facts, Challenges, and Responses," PGDA Working Papers 7111, Program on the Global Demography of Aging.
- Dixit, Avinash K & Stiglitz, Joseph E, 1977.
"Monopolistic Competition and Optimum Product Diversity,"
American Economic Review, American Economic Association, vol. 67(3), pages 297-308, June.
- Dixit, Avinash K & Stiglitz, Joseph E, 1975. "Monopolistic Competition and Optimum Product Diversity," The Warwick Economics Research Paper Series (TWERPS) 64, University of Warwick, Department of Economics.
- Dixit, Avinash K. & Stiglitz, Joseph E., 1975. "Monopolistic Competition And Optimum Product Diversity," Economic Research Papers 268957, University of Warwick - Department of Economics.
- Aghion, Philippe & Howitt, Peter, 1992.
"A Model of Growth through Creative Destruction,"
Econometrica, Econometric Society, vol. 60(2), pages 323-351, March.
- Aghion, P. & Howitt, P., 1989. "A Model Of Growth Through Creative Destruction," University of Western Ontario, Departmental Research Report Series 8904, University of Western Ontario, Department of Economics.
- Aghion, Philippe & Howitt, Peter, 1992. "A Model of Growth Through Creative Destruction," Scholarly Articles 12490578, Harvard University Department of Economics.
- Philippe Aghion & Peter Howitt, 1990. "A Model of Growth Through Creative Destruction," NBER Working Papers 3223, National Bureau of Economic Research, Inc.
- Aghion, P. & Howitt, P., 1990. "A Model Of Growth Through Creative Destruction," DELTA Working Papers 90-12, DELTA (Ecole normale supérieure).
- Aghion, P. & Howitt, P., 1989. "A Model Of Growth Through Creative Destruction," Working papers 527, Massachusetts Institute of Technology (MIT), Department of Economics.
- Daron Acemoglu & Joshua Linn, 2004.
"Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry,"
The Quarterly Journal of Economics, President and Fellows of Harvard College, vol. 119(3), pages 1049-1090.
- Daron Acemoglu & Joshua Linn, 2003. "Market Size in Innovation: Theory and Evidence From the Pharmaceutical Industry," NBER Working Papers 10038, National Bureau of Economic Research, Inc.
- Daron Acemoglu & Joshua Linn, 2004. "Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry," Levine's Working Paper Archive 228400000000000002, David K. Levine.
- Pierre Dubois & Olivier de Mouzon & Fiona Scott-Morton & Paul Seabright, 2015.
"Market size and pharmaceutical innovation,"
RAND Journal of Economics, RAND Corporation, vol. 46(4), pages 844-871, October.
- Dubois, Pierre & de Mouzon, Olivier & Scott Morton, Fiona & Seabright, Paul, 2011. "Market Size and Pharmaceutical Innovation," TSE Working Papers 11-232, Toulouse School of Economics (TSE), revised Mar 2014.
- Dubois, Pierre & de Mouzon, Olivier & Scott Morton, Fiona & Seabright, Paul, 2011. "Market Size and Pharmaceutical Innovation," IDEI Working Papers 670, Institut d'Économie Industrielle (IDEI), Toulouse, revised Mar 2014.
- Seabright, Paul & Scott Morton, Fiona & Dubois, Pierre & de Mouzon, Olivier, 2011. "Market Size and Pharmaceutical Innovation," CEPR Discussion Papers 8367, C.E.P.R. Discussion Papers.
- Patricia M. Danzon & Andrew Epstein & Sean Nicholson, 2007.
"Mergers and acquisitions in the pharmaceutical and biotech industries,"
Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 28(4-5), pages 307-328.
- Patricia M. Danzon & Andrew Epstein & Sean Nicholson, 2004. "Mergers and Acquisitions in the Pharmaceutical and Biotech Industries," NBER Working Papers 10536, National Bureau of Economic Research, Inc.
- Robert J. Barro, 2013.
"Health and Economic Growth,"
Annals of Economics and Finance, Society for AEF, vol. 14(2), pages 329-366, November.
- Robert J. Barro, 2013. "Health and Economic Growth," CEMA Working Papers 572, China Economics and Management Academy, Central University of Finance and Economics.
- Rodrigo Cerda, 2007. "Endogenous innovations in the pharmaceutical industry," Journal of Evolutionary Economics, Springer, vol. 17(4), pages 473-515, August.
- Corchuelo, Beatriz, 2009. "The Effects of Fiscal Incentives for R & D in Spain," DEE - Working Papers. Business Economics. WB wb092302, Universidad Carlos III de Madrid. Departamento de EconomÃa de la Empresa.
- Mohammad Ashraf & Khan A. Mohabbat, 2010. "Output Convergence and the Role of Research and Development," Annals of Economics and Finance, Society for AEF, vol. 11(1), pages 35-71, May.
- Hall, Bronwyn & Van Reenen, John, 2000. "How effective are fiscal incentives for R&D? A review of the evidence," Research Policy, Elsevier, vol. 29(4-5), pages 449-469, April.
- Boldrin,Michele & Levine,David K., 2010.
"Against Intellectual Monopoly,"
Cambridge Books,
Cambridge University Press, number 9780521127264, November.
- Boldrin,Michele & Levine,David K., 2008. "Against Intellectual Monopoly," Cambridge Books, Cambridge University Press, number 9780521879286, November.
- Michele Boldrin & David K Levine, 2008. "Against Intellectual Monopoly," Levine's Bibliography 122247000000002371, UCLA Department of Economics.
- Romer, Paul M, 1990.
"Endogenous Technological Change,"
Journal of Political Economy, University of Chicago Press, vol. 98(5), pages 71-102, October.
- Paul Romer, 1989. "Endogenous Technological Change," NBER Working Papers 3210, National Bureau of Economic Research, Inc.
- Paul M Romer, 1999. "Endogenous Technological Change," Levine's Working Paper Archive 2135, David K. Levine.
- Garber Alan M & Jones Charles I. & Romer Paul, 2006.
"Insurance and Incentives for Medical Innovation,"
Forum for Health Economics & Policy, De Gruyter, vol. 9(2), pages 1-27, March.
- Alan M. Garber & Charles I. Jones & Paul M. Romer, 2006. "Insurance and Incentives for Medical Innovation," NBER Working Papers 12080, National Bureau of Economic Research, Inc.
- Busom, Isabel & Corchuelo, Beatriz & Martinez Ros, Ester, 2012. "Tax incentives or subsidies for R&D?," MERIT Working Papers 2012-056, United Nations University - Maastricht Economic and Social Research Institute on Innovation and Technology (MERIT).
- Toole, Andrew A., 2012. "The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry," Research Policy, Elsevier, vol. 41(1), pages 1-12.
- Michael Kremer, 2002. "Pharmaceuticals and the Developing World," Journal of Economic Perspectives, American Economic Association, vol. 16(4), pages 67-90, Fall.
- Yin, Wesley, 2008. "Market incentives and pharmaceutical innovation," Journal of Health Economics, Elsevier, vol. 27(4), pages 1060-1077, July.
- DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G., 2003. "The price of innovation: new estimates of drug development costs," Journal of Health Economics, Elsevier, vol. 22(2), pages 151-185, March.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Agarwal, Ruchir & Gaule, Patrick, 2022.
"What drives innovation? Lessons from COVID-19 R&D,"
Journal of Health Economics, Elsevier, vol. 82(C).
- Agarwal, Ruchir & Gaule, Patrick, 2021. "What Drives Innovation? Lessons from COVID-19 R&D," IZA Discussion Papers 14079, Institute of Labor Economics (IZA).
- Ruchir Agarwal & Patrick Gaulé, 2021. "What Drives Innovation? Lessons from COVID-19 R&D," IMF Working Papers 2021/048, International Monetary Fund.
- Xavier Vives, 2008.
"Innovation And Competitive Pressure,"
Journal of Industrial Economics, Wiley Blackwell, vol. 56(3), pages 419-469, December.
- Vives, Xavier, 2004. "Innovation and Competitive Pressure," CEPR Discussion Papers 4369, C.E.P.R. Discussion Papers.
- Vives, Xavier, 2006. "Innovation and competitive pressure," IESE Research Papers D/634, IESE Business School.
- Vives, Xavier, 2005. "Innovation and Competitive Pressure," Department of Economics, Working Paper Series qt1s1059vr, Department of Economics, Institute for Business and Economic Research, UC Berkeley.
- Bastian Rake, 2017.
"Determinants of pharmaceutical innovation: the role of technological opportunities revisited,"
Journal of Evolutionary Economics, Springer, vol. 27(4), pages 691-727, September.
- Bastian Rake, 2012. "Determinants of Pharmaceutical Innovation: The Role of Technological Opportunities Revisited," Jena Economics Research Papers 2012-018, Friedrich-Schiller-University Jena.
- Bastian Rake, 2013. "Determinants of Pharmaceutical Innovation: The Role of Technological Opportunities Revisited," DRUID Working Papers 13-03, DRUID, Copenhagen Business School, Department of Industrial Economics and Strategy/Aalborg University, Department of Business Studies.
- Margaret K. Kyle, 2019. "The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals," NBER Chapters, in: Innovation Policy and the Economy, Volume 20, pages 95-123, National Bureau of Economic Research, Inc.
- Gamba, Simona & Magazzini, Laura & Pertile, Paolo, 2021. "R&D and market size: Who benefits from orphan drug legislation?," Journal of Health Economics, Elsevier, vol. 80(C).
- Heidi L. Williams, 2016.
"Intellectual Property Rights and Innovation: Evidence from Health Care Markets,"
Innovation Policy and the Economy, University of Chicago Press, vol. 16(1), pages 53-87.
- Heidi L. Williams, 2015. "Intellectual Property Rights and Innovation: Evidence from Health Care Markets," NBER Chapters, in: Innovation Policy and the Economy, Volume 16, pages 53-87, National Bureau of Economic Research, Inc.
- Heidi L. Williams, 2015. "Intellectual Property Rights and Innovation: Evidence from Health Care Markets," NBER Working Papers 21246, National Bureau of Economic Research, Inc.
- Patricia M. Danzon & Eric L. Keuffel, 2014. "Regulation of the Pharmaceutical-Biotechnology Industry," NBER Chapters, in: Economic Regulation and Its Reform: What Have We Learned?, pages 407-484, National Bureau of Economic Research, Inc.
- Mark Pauly & Kyle Myers, 2016. "A Ricardian-Demand Explanation for Changing Pharmaceutical R&D Productivity," NBER Working Papers 22720, National Bureau of Economic Research, Inc.
- Iizuka, Toshiaki & Uchida, Gyo, 2017.
"Promoting innovation in small markets: Evidence from the market for rare and intractable diseases,"
Journal of Health Economics, Elsevier, vol. 54(C), pages 56-65.
- IIZUKA Toshiaki & UCHIDA Gyo, 2016. "Promoting Innovation in Small Markets: Evidence from the market for rare and intractable diseases," Discussion papers 16036, Research Institute of Economy, Trade and Industry (RIETI).
- Daron Acemoglu & Joshua Linn, 2004.
"Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry,"
The Quarterly Journal of Economics, President and Fellows of Harvard College, vol. 119(3), pages 1049-1090.
- Daron Acemoglu & Joshua Linn, 2003. "Market Size in Innovation: Theory and Evidence From the Pharmaceutical Industry," NBER Working Papers 10038, National Bureau of Economic Research, Inc.
- Daron Acemoglu & Joshua Linn, 2004. "Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry," Levine's Working Paper Archive 228400000000000002, David K. Levine.
- Dosi, Giovanni & Palagi, Elisa & Roventini, Andrea & Russo, Emanuele, 2023.
"Do patents really foster innovation in the pharmaceutical sector? Results from an evolutionary, agent-based model,"
Journal of Economic Behavior & Organization, Elsevier, vol. 212(C), pages 564-589.
- Giovanni Dosi & Elisa Palagi & Andrea Roventini & Emanuele Russo, 2021. "Do patents really foster innovation in the pharmaceutical sector? Results from an evolutionary, agent-based model," LEM Papers Series 2021/37, Laboratory of Economics and Management (LEM), Sant'Anna School of Advanced Studies, Pisa, Italy.
- Giovanni Dosi & Elisa Palagi & Andrea Roventini & Emanuele Russo, 2021. "Do patents really foster innovation in the pharmaceutical sector? Results from an evolutionary, agent-based model," Working Papers hal-04114900, HAL.
- Giovanni Dosi & Elisa Palagi & Andrea Roventini & Emanuele Russo, 2021. "Do patents really foster innovation in the pharmaceutical sector? Results from an evolutionary, agent-based model," SciencePo Working papers Main hal-04114900, HAL.
- Beth Woods & James Lomas & Mark Sculpher & Helen Weatherly & Karl Claxton, 2024. "Achieving dynamic efficiency in pharmaceutical innovation: Identifying the optimal share of value and payments required," Health Economics, John Wiley & Sons, Ltd., vol. 33(4), pages 804-819, April.
- David M. Cutler & Ellen Meara & Seth Richards-Shubik, 2012.
"Induced Innovation and Social Inequality: Evidence from Infant Medical Care,"
Journal of Human Resources, University of Wisconsin Press, vol. 47(2), pages 456-492.
- David M. Cutler & Ellen Meara & Seth Richards, 2009. "Induced Innovation and Social Inequality: Evidence from Infant Medical Care," NBER Working Papers 15316, National Bureau of Economic Research, Inc.
- Boldrin, Michele & Levine, David K., 2008.
"Perfectly competitive innovation,"
Journal of Monetary Economics, Elsevier, vol. 55(3), pages 435-453, April.
- Michele Boldrin & David K Levine, 2000. "Perfectly Competitive Innovation," Levine's Working Paper Archive 1996, David K. Levine.
- Boldrin, Michele & Levine, David K., 2002. "Perfectly Competitive Innovation," CEPR Discussion Papers 3274, C.E.P.R. Discussion Papers.
- Michele Boldrin & David K Levine, 2006. "Perfectly Competitive Innovation," Levine's Working Paper Archive 618897000000000954, David K. Levine.
- Michele Boldrin & David K. Levine, 2002. "Perfectly competitive innovation," Staff Report 303, Federal Reserve Bank of Minneapolis.
- Michele Boldrin & David K Levine, 2002. "Perfectly Competitive Innovation," Levine's Working Paper Archive 625018000000000192, David K. Levine.
- Erzo G. J. Luttmer, 2021. "Dynamic Urn-Ball Discovery," Working Papers 789, Federal Reserve Bank of Minneapolis.
- Yin, Wesley, 2008. "Market incentives and pharmaceutical innovation," Journal of Health Economics, Elsevier, vol. 27(4), pages 1060-1077, July.
- Grossmann, Volker, 2007.
"How to promote R&D-based growth? Public education expenditure on scientists and engineers versus R&D subsidies,"
Journal of Macroeconomics, Elsevier, vol. 29(4), pages 891-911, December.
- Volker Grossmann, 2004. "How to Promote R&D-based Growth? Public Education Expenditure on Scientists and Engineers versus R&D Subsidies," CESifo Working Paper Series 1225, CESifo.
- Mueller-Langer, Frank, 2013. "Neglected infectious diseases: Are push and pull incentive mechanisms suitable for promoting drug development research?," Health Economics, Policy and Law, Cambridge University Press, vol. 8(2), pages 185-208, April.
- Leila Agha & Soomi Kim & Danielle Li, 2020. "Insurance Design and Pharmaceutical Innovation," NBER Working Papers 27563, National Bureau of Economic Research, Inc.
- Hermosilla, Manuel & Wu, Yufei, 2018. "Market size and innovation: The intermediary role of technology licensing," Research Policy, Elsevier, vol. 47(5), pages 980-991.
More about this item
Keywords
Pharmaceutical Industry; Generic Market; Monopolistic Competi- tion; Fiscal Policy.;All these keywords.
JEL classification:
- C63 - Mathematical and Quantitative Methods - - Mathematical Methods; Programming Models; Mathematical and Simulation Modeling - - - Computational Techniques
- H25 - Public Economics - - Taxation, Subsidies, and Revenue - - - Business Taxes and Subsidies
- L65 - Industrial Organization - - Industry Studies: Manufacturing - - - Chemicals; Rubber; Drugs; Biotechnology; Plastics
- O31 - Economic Development, Innovation, Technological Change, and Growth - - Innovation; Research and Development; Technological Change; Intellectual Property Rights - - - Innovation and Invention: Processes and Incentives
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:cuf:journl:y:2015:v:16:i:2:demellosampayo. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Qiang Gao (email available below). General contact details of provider: https://edirc.repec.org/data/emcufcn.html .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.